Monitor the conference presentation for any updates on Phase 3 trial design, enrollment timelines, or regulatory feedback. No immediate trading catalyst from this filing alone.
Price Chart
Executive Summary
OKYO Pharma filed a 6-K announcing a corporate presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will cover the company's pipeline, including plans to initiate a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain (NCP) in the second half of 2026. This is a routine investor-relations event with no new clinical data or financial disclosures.
Key Facts
- OKYO Pharma to present at H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026 at 12:30 PM ET.
- CEO Robert J. Dempsey and CMO Flavio Mantelli will present.
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod in NCP in H2 2026, enrolling ~111 patients.
- No new clinical data, financial results, or material agreements disclosed in this filing.
Financial Impact
No financial impact disclosed; routine conference presentation.
Risk Factors
- Phase 3 trial may face enrollment delays or fail to meet endpoints.
- No new data disclosed; stock may remain range-bound until clinical milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (OKYO) — Batch item 1 | 0001493152-26-034019 |
| Exhibit: ex99-1.htm | 0001493152-26-034019 |
| Document: 0001493152-26-034019-index-headers.html | 0001493152-26-034019 |
| Document: 0001493152-26-034019-index.html | 0001493152-26-034019 |
| Document: 0001493152-26-034019.txt | 0001493152-26-034019 |
| 6-K Filing (OKYO) — Batch item 6 | 0001493152-26-034019 |
| Exhibit: ex99-1.htm | 0001493152-26-034019 |
| Document: 0001493152-26-034019-index-headers.html | 0001493152-26-034019 |
| Document: 0001493152-26-034019-index.html | 0001493152-26-034019 |
| Document: 0001493152-26-034019.txt | 0001493152-26-034019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers